Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 12, Décembre 2008
Page(s) 1083 - 1088
Section M/S revues
DOI https://doi.org/10.1051/medsci/200824121083
Publié en ligne 15 décembre 2008
  1. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994; 12 : 141–79.
  2. Barnes PJ, Karin M. Nuclear factor-κB : a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336 : 1066–71.
  3. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002; 3 : 221–7.
  4. Karin M, Cao Y, Greten F, Li ZW. NF-κB in cancer : from innocent bystander to major culprit. Nat Rev Cancer 2002; 2 : 301–10.
  5. Rayet B, Gélinas C. Aberrant Rel/NF-kB genes and activity in human cancer. Oncogene 1999; 18 : 6938–47.
  6. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance : enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999; 5 : 412–17.
  7. Gilmore TD. NF-kappa B, KBF1, dorsal, and related matters. Cell 1990; 62 : 841–3.
  8. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination : the control of NF-κB activity. Annu Rev Immunol 2000; 18 : 621–63.
  9. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology : pitfalls and promises for future drug development. Biochem Pharmacol 2006; 72 : 1161–79.
  10. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004; 279 : 26243–50.
  11. Derudder E, Dejardin E, Pritchard LL, et al. RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation : critical roles for p100. J Biol Chem 2003; 278 : 23278–84.
  12. Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17 : 525–35.
  13. Jacque E, Tchenio T, Piton G, et al. RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc Natl Acad Sci USA 2005; 102 : 14635–40.
  14. Jacque E, Baud V. RelA, un nouvel acteur dans la régulation de l’activité de RelB. Med Sci (Paris) 2006; 22 : 113–4.
  15. Gautheron J, Courtois, G. Les nouvelles fonctions de NEMO, la sous-unité régulatrice de la kinase activant NF-κB. Med Sci (Paris) 2008; 24 : 954–60.
  16. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12 : 115–30.
  17. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12 : 131–44.
  18. Stoffel A, Chaurushiya M, Singh B, Levine AJ. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci USA 2004; 101 : 9079–84.
  19. Mineva RD, Rothstein TL, Meyers JA, et al. CD40 ligand-mediated activation of the de novo RelB NF-kB synthesis pathway in transformed B cells promotes rescue from apoptosis. J Biol Chem 2007; 282 : 17475–85.
  20. Dos Santos NR, Williame M, Gachet S, et al. RelB-dependent stromal cells promote T-cell leukemogenesis. PLos One 2008; 3 : e2555.
  21. Zhang J, Chang CC, Lombardi L, Dalla-Favera R. Rearranged NFκB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 1994; 9 : 1931–7.
  22. Neri A, Fracchiolla NS, Migliazza A, et al. The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Leuk Lymphoma 1996; 23 : 43–8.
  23. Derudder E, Laferte A, Ferreira V, et al. Identification and characterization of p100HB, a new mutant form of p100/NF-kappa B2. Biochem Biophys Res Commun 2003; 308 : 744–9.
  24. Hacker H, Karin M. Is NF-kappaB2/p100 a direct activator of programmed cell death ? Cancer Cell 2002; 2 : 431–3.
  25. Malinge S, Monni R, Bernard O, Penard-Lacronique V. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 2006; 25 : 3589–97.
  26. Demicco EG, Kavanagh KT, Romieu-Mourez R, et al. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol 2005; 25 : 10136–47.
  27. Romieu-Mourez R, Kim DW, Shin SM, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003; 23 : 5738–54.
  28. Connelly L, Robinson-Benion C, Chont M, et al. A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis. J Biol Chem 2007; 282 : 10028–35.
  29. Wang X, Belguise K, Kersual N, et al. Estrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007; 9 : 470–8.
  30. Lessard L, Begin LR, Gleave ME, et al. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer : an immunohistochemical study. Br J Cancer 2005; 93 : 1019–23.
  31. Josson S, Xu Y, Fang F, et al. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 2006; 25 : 1554–9.
  32. Xu Y, Fang F, St Clair DK, et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 2007; 6 : 2048–56.
  33. Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 1999; 284 : 316–20.
  34. Liu B, Park E, Zhu F, et al. A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci USA 2006; 103 : 17202–7.
  35. Park E, Zhu F, Liu B, et al. Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas. Cancer Res 2007; 67 : 9158–68.
  36. Zhu F, Xia X, Liu B, et al. IKKalpha shields 14-3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing. Mol Cell 2007; 27 : 214–27.
  37. Lobry C, Weil R. Mécanismes régulateurs de la voie NF-κB dans les lymphocytes T. Med Sci (Paris) 2007; 23 : 857–61.
  38. Lobry C, Weil R. Nouveaux mécanismes régulateurs de Bcl10 : Une avancée dans la compréhension de la survenue des lymphomes du MALT ? Med Sci (Paris) 2007; 23 : 353–5.
  39. Romagnoli M, Séveno C, Bataille R, Barillé-Nion S. Survivine en cancérologie : aspects moléculaires et applications thérapeutiques. Med Sci (Paris) 2008; 24 : 821–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.